Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a ...

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq ...